Synopsis: The partnership will expand access to Guardant Health’s Shield™ Multi-Cancer Detection (MCD) blood test, enabling screening for 10 common cancers through a single blood sample and strengthening early cancer detection across India.
This partnership is more than a routine distribution agreement. It enables Zydus to enter India’s underpenetrated early cancer screening market through an asset-light model. By combining Guardant Health’s advanced screening technology, Apollo Hospitals’ nationwide network, and Zydus’ oncology expertise, the company is strengthening its long-term position in the fast-growing precision diagnostics segment.
Zydus Lifesciences Limited is currently trading at Rs 1,150. The stock opened at Rs 1,145, reached a day’s high of Rs 1,151.9, and has so far recorded a day’s low of Rs 1,131.6. The current market capitalisation of the company is Rs 1,15,264 crore, and it is trading at a P/E ratio of 21.2, which is lower than the industry peer median of 34.9
What is Shield MCD?
Shield MCD is a single blood test that screens for 10 common cancers, including lung, breast, colorectal, gastric and pancreatic cancers, compared to traditional screening that often requires separate tests for different organs.
The test has been awarded the U.S. Food and Drug Administration (FDA) Breakthrough Device Designation for its novel screening potential. It is designed primarily for people who are 45 and older and at average risk for cancer, dramatically increasing the chance of early, life-saving detection.
Understand the Partnership
Zydus Lifesciences has signed a Memorandum of Understanding (MoU) with Apollo Hospitals to make the Shield™ Multi-Cancer Detection (MCD) test available across India. Guardant Health developed the technology, and Zydus holds the exclusive rights to commercialise the test in India. Zydus is already recognized as one of India’s leading oncology drug manufacturers, actively expanding its pipeline of affordable biosimilars and targeted therapies
Zydus is scaling the technology with Apollo Hospitals, the world’s largest integrated healthcare platform. Apollo has a network of over 2,500 diagnostic centres and 78 top hospitals with over 10,900 beds. By plugging Shield™ directly into Apollo’s established institutional referral pipelines, Zydus instantly gains access to an enterprise consumer base that is already health-conscious and possesses the purchasing power to afford premium molecular screening tiers. Through Apollo Hospitals’ nationwide network, more people will now have access to this advanced cancer screening test.
Financials
The company reported a strong Q4 FY26 performance with revenues growing 10.5 Percent QoQ to Rs 7,587 crore from Rs 6,864 crore in Q3 FY26 and 16.2 Percent YoY from Rs 6,528 crore in Q4 FY25. Operating profit rose 40.7 Percent QoQ to Rs 2,554 crore from Rs 1,816 crore and 20.1 Percent YoY from Rs 2,126 crore. Operating profit margin (OPM) rose to 34 Percent from 26 Percent in the previous quarter and 33 Percent in the same quarter last year, indicating improved operating efficiency.
Profitability was strong in the quarter. Profit before tax (PBT) was up 22.7 Percent QoQ to Rs 1,660 crore from Rs 1,353 crore, but was down 0.7 Percent YoY from Rs 1,672 crore in Q4 FY25. Net profit increased by 31.1 Percent QoQ to Rs 1,341 crore from Rs 1,023 crore and 7.8 Percent YoY from Rs 1,244 crore. EPS also rose to Rs 12.65 from Rs 10.36 in Q3 FY26 and Rs 11.64 in Q4 FY25.
The company is still well placed financially with cash and cash equivalents of Rs 1,417 crore, working capital of Rs 4,194 crore and a current ratio of 1.27x. Additionally, it has a moderate debt profile with a debt-to-equity ratio of 0.46x, which provides financial flexibility for future growth initiatives.
From a profitability perspective, the company continues to generate strong returns with ROCE of 21.2 Percent, ROE of 21.2 Percent and ROA of 12.4 Percent. Over the long term, the company has delivered a 3-year sales CAGR of 16 Percent and a 3-year profit CAGR of 32 Percent, demonstrating strong, consistent earnings growth and operational execution.
What Does Management Say?
“The collaboration aims to make early cancer screening accessible and patient-friendly across India,” the management said. The collaboration aims to boost early diagnosis, encourage preventive healthcare, and expand access to precision cancer diagnostics to improve patient outcomes, using Guardant Health’s advanced screening technology, Apollo Hospitals’ healthcare network and Zydus Lifesciences’ oncology expertise.
Zydus Lifesciences Limited is one of the leading pharmaceutical companies of India with a presence in the global pharmaceutical landscape that is engaged in the discovery, development, manufacturing and marketing of a wide range of healthcare products. The company has a strong global footprint with operations in more than 50 countries and is growing its footprint in innovative healthcare, precision diagnostics and oncology solutions.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
